Form 4: Crinetics Pharmaceuticals Executive Exercises Options and Sells Shares
SEC Form 4 Filing
Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, exercised stock options and sold shares on July 3, 2024, according to a recent SEC filing.
Summary
- On July 3, 2024, Dana Pizzuti, the Chief Medical and Development Officer of Crinetics Pharmaceuticals, exercised stock options to acquire 14,375 shares of common stock at a price of $16.89 per share.
- Simultaneously, Pizzuti sold 14,375 shares in the open market at a volume-weighted average price of $44.87 per share, with prices ranging from $44.24 to $45.55.
- Following these transactions, Pizzuti directly owns 28,507 shares of Crinetics Pharmaceuticals common stock.
- Pizzuti also holds options to purchase 153,417 shares.
- The sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan.
Sentiment
Score: 5
Explanation: The document is a neutral report of insider trading activity. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.
Future Outlook
There is no future outlook provided in this document.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to exercise stock options and sell a portion of the acquired shares for personal financial management. The use of a 10b5-1 trading plan suggests the transactions were pre-planned to avoid any appearance of trading on inside information.
Comparison to Industry Standards
- Executive compensation packages often include stock options as a form of long-term incentive.
- The exercise and sale of shares by executives are common and are typically disclosed through SEC filings like Form 4.
- Rule 10b5-1 trading plans are frequently used by corporate insiders to schedule stock sales in advance, ensuring compliance with insider trading regulations.
- Comparing Pizzuti's transactions to those of executives at similar-sized biotech companies (e.g., Neurocrine Biosciences, Global Blood Therapeutics prior to acquisition) would provide context on the scale and frequency of such activities.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it represents a small percentage of the total outstanding shares.
- The use of a 10b5-1 plan ensures transparency and reduces the risk of insider trading concerns.
Key Dates
| Date | Description |
|---|---|
| 09/30/2023 | 25% of the shares subject to the option vest |
| 07/03/2024 | Date of transaction: exercise of stock options and sale of shares. |
| 07/05/2024 | Date of signature on the Form 4 filing. |
| 10/10/2032 | Expiration date of the stock option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.